Two Worlds Collide When Anime Heroes From DanMachi Meet KonoSuba: Fantastic Days Starting May 26!
Today, leading game publisher Nexon announced free-to-play mobile RPG KonoSuba: Fantastic Days will be teaming up with the popular light novel and manga series, DanMachi, for a limited time crossover event from May 26 to June 9. The anime worlds of KonoSuba: Fantastic Days and DanMachi collide in an all new fantastical encounter!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220512006001/en/
Nexon America KonoSuba: Fantastic Days! X DanMachi Collaboration (Graphic: Business Wire)
In DanMachi, a naive adventurer from the city of Orario named Bell Cranel embarks on a perilous quest in the dungeon-like catacombs underneath the city to fight monsters and a mysterious power. Along the way, Bell meets Hestia, a lonely goddess, and Ais Wallenstein, a powerful swordswoman, plus other new friends who act as his guide through the dangerous Dungeon. The KonoSuba: Fantastic Days X DanMachi collaboration treats Konofans to the unique characters and storylines from the worlds of Axel and Orario.
Konofans can pre-register starting May 12 - 25 here. Once registered, players will be able to earn special rewards through participating in the following events held on the page:
- Pre-register for Adventure!: The higher the number of cumulative pre-registers, the richer the rewards will be for all players! Players will be eligible to receive these rewards for each milestone achieved in-game from May 12 - 25.
- Countdown Bonus: Claim additional 300 Quartz daily as a countdown bonus from May 21 - 25.
- Login Bonuses: From May 26 to June 9, claim special collaboration event login bonuses every day, including two 4★ Guaranteed Recruit Tickets, a free 10x Recruit Ticket, and many other reward items during the two week period!
The KonoSuba: Fantastic Days X DanMachi events include:
- Goddess Rivalry:DanMachi’s goddess, Hestia, faces off against Konosuba’s Aqua in a new quest and story!
- Panel Missions: A new feature exclusive to this collaboration event will be introduced that rewards various items and new stones upon clearing missions.
- New Universal Missions awaits players whose shared goal and progress depend on the number of defeats of new boss, Minotaur.
- A challenging new Dungeon beckons fearless adventurers!
KonoSuba: Fantastic Days is published by Nexon in partnership with KonoSuba publisher Kadokawa, and developed by Sumzap. ©2019 N・K／K／KMP ©Sumzap, Inc. ©NEXON All Rights Reserved. ©FO-SBCr/D4
To stay up-to-date on KonoSuba: Fantastic Days, visit the Google Play or App Store page, and be sure to follow @PlayKonoSuba on Instagram and Twitter for the latest news!
Assets: Press Assets
Social Media: Twitch / Twitter / Instagram / Discord / Facebook
About DanMachi
Is It Wrong to Try to Pick Up Girls in a Dungeon? (also known as DanMachi for short) is based on Fujino Omori’s light novel of the same name which sold more than 12 million copies in total. The story follows the fresh faced Bell Cranel and his growth as he adventures through a giant city called Orario and explores the massive labyrinth “Dungeon” nestled underneath the city.
About KonoSuba: Fantastic Days konosuba.nexon.com
Based on the popular anime series “KonoSuba: God's Blessing on this Wonderful World!”, KonoSuba: Fantastic Days is a free-to-play character-collection RPG for iOS and Android. Featuring fan-favorite characters, including Kazuma Satou, Aqua, Megumin and Darkness, the game follows the storyline from the original novel and includes bespoke characters created exclusively for the game. Last year, the Japanese release of KonoSuba: Fantastic Days saw great success, garnering recognition from players and praise from the KonoSuba fan base.
About Nexon America Inc.https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220512006001/en/
Contact information
Brian Klotz
Nexon America
NA_pr@nexon.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom